Management of Blighted Ovum (Anembryonic Pregnancy)
Patients with a blighted ovum should be offered all three management options—expectant, medical (preferably mifepristone-misoprostol combination), or procedural (uterine aspiration)—with choice guided by shared decision-making, as all are equally safe and effective 1.
Diagnostic Confirmation
Before initiating treatment, confirm the diagnosis using established ultrasound criteria:
- Gestational sac mean diameter ≥25 mm without an embryo is diagnostic of pregnancy loss 2
- If initial ultrasound shows a gestational sac without a yolk sac, wait at least 14 days before diagnosing failed pregnancy if no embryonic cardiac activity develops 2
- Critical pitfall: An intrauterine sac-like structure can be a pseudogestational sac from ectopic pregnancy—ensure β-hCG levels and serial imaging support true intrauterine pregnancy before proceeding 3
Treatment Options
Medical Management (Preferred Pharmacologic Approach)
The combined mifepristone-misoprostol regimen is superior to misoprostol alone and should be the first-line medical option 1, 4:
- Mifepristone 200 mg orally, followed 7-48 hours later by misoprostol 800 mcg vaginally or buccally 1
- This combination achieves 83-88% success rates 4, 5
- Key advantage: Mifepristone pretreatment improves success regardless of baseline clinical factors (adjusted OR 2.51) 4
If mifepristone is unavailable:
- Misoprostol alone: 600-800 mcg sublingually or vaginally, repeated at least once at 3-hour intervals 1
- Success rates are lower (69-71% for anembryonic pregnancy) 4, 6
Pain management: Ibuprofen 800 mg orally 1
Expectant Management
- Highly effective for incomplete abortion but less effective for anembryonic pregnancy compared to active management 6
- Can continue up to 8 weeks after diagnosis if no medical complications or urgent symptoms develop 1
- Requires patient comfort with uncertainty and access to urgent care if needed
Procedural Management (Uterine Aspiration)
- Preferred over dilation and curettage: equally safe, faster, more cost-effective, and suitable for outpatient settings 6
- Most predictable timeline for completion
- Consider for patients desiring rapid resolution or those with failed medical management
Post-Treatment Monitoring
- Do not require in-person confirmation of completion for all patients—offer but don't mandate 1
- Do not use endometrial thickness alone as criterion for additional intervention 1
- Risk factors for complications after medical management include:
- Higher β-hCG levels 14 days post-procedure
- Absence of tissue expulsion during initial treatment 5
Important Caveats
- Rh testing and RhoGAM are NOT recommended before 12 weeks gestation for medical management 1
- No baseline clinical factors (bleeding, parity, gestational age) reliably predict medical management success—mifepristone addition is the only proven predictor 4
- Complications requiring additional visits or hospitalization occur in approximately 9% of cases 5
- All three management approaches have equivalent safety profiles; patient preference should drive the decision 1, 6